Literature DB >> 33138965

Polypharmacy and emergency readmission to hospital after critical illness: a population-level cohort study.

Angus J Turnbull1, Eddie Donaghy2, Lisa Salisbury3, Pamela Ramsay4, Janice Rattray5, Timothy Walsh6, Nazir Lone2.   

Abstract

BACKGROUND: Polypharmacy is common and closely linked to drug interactions. The impact of polypharmacy has not been previously quantified in survivors of critical illness who have reduced resilience to stressors. Our aim was to identify factors associated with preadmission polypharmacy and ascertain whether polypharmacy is an independent risk factor for emergency readmission to hospital after discharge from a critical illness.
METHODS: A population-wide cohort study consisting of patients admitted to all Scottish general ICUs between January 1, 2011 and December 31, 2013, whom survived their ICU stay. Patients were stratified by presence of preadmission polypharmacy, defined as being prescribed five or more regular medications. The primary outcome was emergency hospital readmission within 1 yr of discharge from index hospital stay.
RESULTS: Of 23 844 ICU patients, 29.9% were identified with polypharmacy (n=7138). Factors associated with polypharmacy included female sex, increasing age, and social deprivation. Emergency 1-yr hospital readmission was significantly higher in the polypharmacy cohort (51.8% vs 35.8%, P<0.001). After confounder adjustment, patients with polypharmacy had a 22% higher hazard of emergency 1-yr readmission (adjusted hazard ratio 1.22, 95% confidence interval 1.16-1.28, P<0.001). On a linear scale of polypharmacy each additional prescription conferred a 3% increase in hazard of emergency readmission by 1 yr (adjusted hazard ratio 1.03, 95% confidence interval 1.02-1.03, P<0.001).
CONCLUSIONS: This national cohort study of ICU survivors demonstrates that preadmission polypharmacy is an independent risk factor for emergency readmission. In an ever-growing era of polypharmacy, this risk factor may represent a substantial burden in the at-risk post-intensive care population.
Copyright © 2020 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  critical illness; drug interactions; emergency readmission; hospital readmission; intensive care; outcome; polypharmacy

Mesh:

Year:  2020        PMID: 33138965      PMCID: PMC8014911          DOI: 10.1016/j.bja.2020.09.035

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  28 in total

1.  Predicting risk of unplanned hospital readmission in survivors of critical illness: a population-level cohort study.

Authors:  Nazir I Lone; Robert Lee; Lisa Salisbury; Eddie Donaghy; Pamela Ramsay; Janice Rattray; Timothy S Walsh
Journal:  Thorax       Date:  2018-04-05       Impact factor: 9.139

2.  Impact of potentially inappropriate medications and polypharmacy on 3-month readmission among older patients discharged from acute care hospital: a prospective study.

Authors:  Paolo Fabbietti; Giuseppina Di Stefano; Raffaella Moresi; Laura Cassetta; Mirko Di Rosa; Filippo Fimognari; Valentina Bambara; Giovanni Ruotolo; Alberto Castagna; Carmen Ruberto; Fabrizia Lattanzio; Andrea Corsonello
Journal:  Aging Clin Exp Res       Date:  2017-11-11       Impact factor: 3.636

3.  Impact of pharmacist involvement in the transitional care of high-risk patients through medication reconciliation, medication education, and postdischarge call-backs (IPITCH Study).

Authors:  Arti Phatak; Rachael Prusi; Brooke Ward; Luke O Hansen; Mark V Williams; Elizabeth Vetter; Noelle Chapman; Michael Postelnick
Journal:  J Hosp Med       Date:  2015-10-05       Impact factor: 2.960

4.  Analysis of potential drug-drug interactions in medical intensive care unit patients.

Authors:  Esther V Uijtendaal; Lieke L M van Harssel; Gerard W K Hugenholtz; Emile M Kuck; Jeannette E F Zwart-van Rijkom; Olaf L Cremer; Toine C G Egberts
Journal:  Pharmacotherapy       Date:  2014-01-04       Impact factor: 4.705

5.  Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals.

Authors:  Paul Gallagher; Pierre Olivier Lang; Antonio Cherubini; Eva Topinková; Alfonso Cruz-Jentoft; Beatriz Montero Errasquín; Pavla Mádlová; Beatrice Gasperini; Hilde Baeyens; Jean-Pierre Baeyens; Jean-Pierre Michel; Denis O'Mahony
Journal:  Eur J Clin Pharmacol       Date:  2011-05-17       Impact factor: 2.953

6.  Increasing polypharmacy - an individual-based study of the Swedish population 2005-2008.

Authors:  Bo Hovstadius; Karl Hovstadius; Bengt Astrand; Göran Petersson
Journal:  BMC Clin Pharmacol       Date:  2010-12-02

7.  Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.

Authors:  Julie Doan; Hubert Zakrzewski-Jakubiak; Julie Roy; Jacques Turgeon; Cara Tannenbaum
Journal:  Ann Pharmacother       Date:  2013-03-12       Impact factor: 3.154

8.  Trends in Polypharmacy in Japan: A Nationwide Retrospective Study.

Authors:  Hiroshi Onoue; Toshihiro Koyama; Yoshito Zamami; Hideharu Hagiya; Yasuhisa Tatebe; Naoko Mikami; Kazuaki Shinomiya; Yoshihisa Kitamura; Shiro Hinotsu; Toshiaki Sendo; Yasuyoshi Ouchi; Mitsunobu R Kano
Journal:  J Am Geriatr Soc       Date:  2018-10-06       Impact factor: 5.562

9.  PReventing early unplanned hOspital readmission aFter critical ILlnEss (PROFILE): protocol and analysis framework for a mixed methods study.

Authors:  Timothy S Walsh; Lisa Salisbury; Eddie Donaghy; Pamela Ramsay; Robert Lee; Janice Rattray; Nazir Lone
Journal:  BMJ Open       Date:  2016-06-28       Impact factor: 2.692

10.  Prevalence and predictors of polypharmacy among Korean elderly.

Authors:  Hong-Ah Kim; Ju-Young Shin; Mi-Hee Kim; Byung-Joo Park
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

View more
  7 in total

Review 1.  Long-term recovery after critical illness in older adults.

Authors:  Ramya Kaushik; Lauren E Ferrante
Journal:  Curr Opin Crit Care       Date:  2022-08-11       Impact factor: 3.359

Review 2.  The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review.

Authors:  Georgie B Lee; Christopher Etherton-Beer; Sarah M Hosking; Julie A Pasco; Amy T Page
Journal:  Ther Adv Drug Saf       Date:  2022-07-04

Review 3.  The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications.

Authors:  Amir Hossein Miri; Mojtaba Kamankesh; Antoni Llopis-Lorente; Chenguang Liu; Matthias G Wacker; Ismaeil Haririan; Hamid Asadzadeh Aghdaei; Michael R Hamblin; Abbas Yadegar; Mazda Rad-Malekshahi; Mohammad Reza Zali
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

4.  Incidence and Risk Factors for 28 Days Hospital Readmission: A Retrospective Study from Oman.

Authors:  Maitha Al Sibani; Juhaina Salim Al-Maqbali; Zainab Yusuf; Abdullah Mohammed Al Alawi
Journal:  Oman Med J       Date:  2022-09-30

5.  Clinical and nutritional predictors of hospital readmission within 30 days.

Authors:  Paula Luiza Menezes Cruz; Bruna Lúcia de Mendonça Soares; Jacqueline Elineuza da Silva; Renata Reis de Lima E Silva
Journal:  Eur J Clin Nutr       Date:  2021-05-26       Impact factor: 4.016

6.  Does a screening checklist for complex health and social care needs have potential clinical usefulness for predicting unplanned hospital readmissions in intensive care survivors: development and prospective cohort study.

Authors:  Timothy Simon Walsh; Ellen Pauley; Eddie Donaghy; Joanne Thompson; Lucy Barclay; Richard Anthony Parker; Christopher Weir; James Marple
Journal:  BMJ Open       Date:  2022-03-23       Impact factor: 2.692

7.  Medication-related interventions to improve medication safety and patient outcomes on transition from adult intensive care settings: a systematic review and meta-analysis.

Authors:  Richard S Bourne; Jennifer K Jennings; Maria Panagioti; Alexander Hodkinson; Anthea Sutton; Darren M Ashcroft
Journal:  BMJ Qual Saf       Date:  2022-01-18       Impact factor: 7.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.